The estimated Net Worth of James M Gatling is at least $14.9 Milion dollars as of 8 November 2010. James Gatling owns over 170,300 units of Baxter International stock worth over $12,643,369 and over the last 22 years James sold BAX stock worth over $2,276,500.
James has made over 10 trades of the Baxter International stock since 2003, according to the Form 4 filled with the SEC. Most recently James exercised 170,300 units of BAX stock worth $7,040,202 on 8 November 2010.
The largest trade James's ever made was exercising 170,300 units of Baxter International stock on 8 November 2010 worth over $7,040,202. On average, James trades about 10,218 units every 62 days since 2003. As of 8 November 2010 James still owns at least 321,960 units of Baxter International stock.
You can see the complete history of James Gatling stock trades at the bottom of the page.
James's mailing address filed with the SEC is , , , , .
Over the last 22 years, insiders at Baxter International have traded over $966,809,165 worth of Baxter International stock and bought 178,227 units worth $6,261,495 . The most active insiders traders include Point Llc Loeb Daniel S Third, Michael F Mahoney oraz Jeffrey A Craig. On average, Baxter International executives and independent directors trade stock every 37 days with the average trade being worth of $3,609,738. The most recent stock trade was executed by Jeanne K Mason on 1 March 2024, trading 64,488 units of BAX stock currently worth $2,397,019.
baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
Baxter International executives and other stock owners filed with the SEC include: